Leila Rastegar Zegna

Leila Rastegar Zegna has a wealth of work experience. Leila has been a Founding General Partner at Kindred Capital VC since 2015. In 2017, they became a Board Director at LabGenius, and in 2018 joined Pave as a Board Director. In 2019, they joined the Board of Directors of Nomio and the Kabuki Syndrome Foundation, and became a Board Member of Ori Biotech. In 2020, they became a Board Director at Gaia and Nomio. In 2021, they were appointed a Trust Board Member at Boston Children's Hospital and a Board Member at Eleven Therapeutics. Additionally, they have been an Angel Investor in multiple start-ups since 2011, including Matterport, ID. me, Bloom & Wild, Gousto, Thread, Sure, HealX, AllStripes, Lumen, Memrise, Enki, and others.

Leila Rastegar Zegna attended Yale University from 2001 to 2005, where they earned a BA in Mathematics & Philosophy. Leila then went on to Harvard Business School from 2009 to 2011, where they earned an MBA.